pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Foundayo · news · pharmadog
← back to Foundayo
News mentioning Foundayo
32
stories
1d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
8d
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
9d
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
stat
10d
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
stat
15d
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
15d
Lilly climbs, Novo falls as obesity drug battle intensifies
biopharma dive
15d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
15d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
20d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
20d
Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
biospace
28d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
28d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
28d
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 7, 26
Kailera says obesity pill succeeds in late-stage trial in China
biopharma dive
Jul 2, 26
STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
stat
Jun 11, 26
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
stat
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 8, 26
STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
stat
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
May 28, 26
Lilly obesity meds Foundayo and Zepbound to gain CVS coverage
endpoints
May 28, 26
CVS obesity drug deal puts Lilly on equal footing with Novo
biopharma dive
May 13, 26
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
biopharma dive
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 12, 26
Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
endpoints
May 8, 26
Lilly to invest extra $4.5B across Indiana manufacturing
biopharma dive
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
May 6, 26
Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
endpoints
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
← prev
page 1 of 2
next →
